Diadema Partners’s Pacira BioSciences PCRX Stock Holding History

Diadema Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-48,025	Closed	-$1.24M	–	186
2025 Q4	$1.24M	Sell	48,025 -10,901	-18%	-$259K	0.21%	86
2025 Q3	$1.52M	Hold	58,926	–	–	0.39%	71
2025 Q2	$1.41M	Buy	58,926 +20,000	+51%	+$504K	0.43%	55
2025 Q1	$967K	Buy	+38,926	New	+$932K	0.25%	66

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Diadema Partners's PCRX Position: Q1 2026 in Review

Diadema Partners sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 48,025 shares — an estimated $1.24M sold.

Diadema Partners first reported a position in PCRX in Q1 2025 and held it in 4 quarters. The position peaked at $1.52M in Q3 2025. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Diadema Partners reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 48,025 Pacira BioSciences shares in Q1 2026, an estimated $1.24M.
Diadema Partners first reported a position in Pacira BioSciences in Q1 2025 and held it in 4 quarters.
Diadema Partners's Pacira BioSciences position peaked at $1.52M in Q3 2025.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.